Loading
PRKN (E3 ubiquitin-protein ligase parkin) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Ovarian cancer.
Functions within a multiprotein E3 ubiquitin ligase complex, catalysing the covalent attachment of ubiquitin moieties onto substrate proteins. Substrates include SYT11 and VDAC1. Other substrates are BCL2, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPTIN5, TOMM20, USP30, ZNF746, MIRO1 and AIMP2.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Phosphatidylinositide 3-Kinase Inhibitor. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.85).
In plain words · PRKN (E3 ubiquitin-protein ligase parkin) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Ovarian cancer.
PRKN (E3 ubiquitin-protein ligase parkin) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Ovarian cancer.
Functions within a multiprotein E3 ubiquitin ligase complex, catalysing the covalent attachment of ubiquitin moieties onto substrate proteins. Substrates include SYT11 and VDAC1.
No product in this corpus aims at PRKN yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PRKN: RNA tissue enhanced (skeletal muscle 27 nTPM, tongue 15 nTPM); high antibody staining in 5 normal tissues; highest cancer staining pancreatic cancer (2 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Ovarian cancer); Open Targets associates it with 2 specific cancer types at or above 0.5 (lung cancer, ovarian cancer). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PRKN tissue; Open Targets ENSG00000185345 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Kitada et al, Nature, 1998, "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism". Source.
Sources: HGNC HGNC:8607 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O60260 (protein name, function text, keywords and locations (REST API)); CIViC gene PRKN (2 evidence items, 0 assertions, 2 variants; diseases: Cancer (GraphQL API, CC0)); Open Targets ENSG00000185345 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: ovarian cancer 0.57, lung cancer 0.58 (GraphQL API, CC0))
Functions within a multiprotein E3 ubiquitin ligase complex, catalysing the covalent attachment of ubiquitin moieties onto substrate proteins. Substrates include SYT11 and VDAC1. Other substrates are BCL2, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPTIN5, TOMM20, USP30, ZNF746, MIRO1 and AIMP2. Mediates monoubiquitination as well as 'Lys-6', 'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognised by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP, possibly playing a role in Lewy-body formation. Location: Cytoplasm, cytosol; Nucleus; Endoplasmic reticulum; Mitochondrion (UniProt). Locus 6q26 (HGNC).
RNA: tissue enhanced (skeletal muscle 27 nTPM, tongue 15 nTPM), detected in many normal tissues.
Medium: Adrenal gland, Appendix, Breast, Bronchus, Colon, Duodenum, Endometrium, Epididymis.
RNA cancer enhanced: Kidney Chromophobe 10 pTPM.
Medium only: cervical cancer, colorectal cancer, lung cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PRKN" OR ABSTRACT:"PRKN" OR TITLE:"parkin RBR E3 ubiquitin protein ligase" OR ABSTRACT:"parkin RBR E3 ubiquitin protein ligase" OR TITLE:"E3 ubiquitin-protein ligase parkin" OR ABSTRACT:"E3 ubiquitin-protein ligase parkin" OR TITLE:"AR-JP" OR ABSTRACT:"AR-JP" OR TITLE:"parkin" OR ABSTRACT:"parkin" OR TITLE:"PARK2" OR ABSTRACT:"PARK2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRKN, not a curated reading list.